NCT04690322View on ClinicalTrials.gov

POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

PHASE4RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Hemophilia AFactor VIII
Interventions
DRUG

Eloctate

Eloctate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.

DRUG

Adynovate

Adynovate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.

DRUG

Emicizumab

Emicizumab is FDA-approved to treat patients with Hemophilia A. This drug will be used for non-factor VIII-based replacement therapy.

Trial Locations (1)

75235

RECRUITING

The University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER